Body composition and bone metabolism in young gaucher disease type I patients treated with imiglucerase

European Journal of Medical Research

Volumn 13, Issue 1, 2008, Pages 31-38

  Parisi, Muriel S ^a,b   Mastaglia, S R ^a   Bagur, A ^a   Goldstein, G ^a   Zeni, S N ^a   Oliveri, B ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b NONE   (Argentina)

Author keywords

Body composition; Bone mineral density; Bone turnover markers; DXA; Gaucher disease; Imiglucerase

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; CHITOTRIOSIDASE; CREATININE; IMIGLUCERASE; OSTEOCALCIN; TELOPEPTIDE;

ADULT; ARTICLE; BLOOD ANALYSIS; BODY COMPOSITION; BODY FAT; BODY MASS; BONE DENSITY; BONE MARROW DEPRESSION; BONE MASS; BONE METABOLISM; BONE MINERAL; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME REPLACEMENT; FEMALE; GAUCHER DISEASE; GLUCOSE METABOLISM; HUMAN; HYPERMETABOLISM; LEAN BODY WEIGHT; LIPID METABOLISM; LOW DRUG DOSE; MALE; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; STATISTICAL SIGNIFICANCE;

ABSORPTIOMETRY, PHOTON; ADIPOSE TISSUE; ADULT; BODY COMPOSITION; BODY WEIGHT; BONE AND BONES; BONE DENSITY; CALCIUM; COLLAGEN TYPE I; CREATININE; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HEXOSAMINIDASES; HUMANS; MALE; MIDDLE AGED; OSTEOCALCIN; PEPTIDES; VITAMIN D;

EID: 38949211044     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Andersson HC, Charrow J, Kaplan P, Mistry P, Pastores GM, Prakash-Cheng A, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ: International Collaborative Gaucher Groups U.S. Regional Coordinators. Individualization of long-term enzyme replacement therapy for Gaucher Disease. Genet Med. 2005; 7:105-10.
2. Alfonso P, Cenarro A, Perez-Calvo JI, Puzo J, Giralt M, Giraldo P, Pocovi M. Effect of enzyme replacement therapy on lipid profile in patients with Gaucher's disease. Med Clin (Barc). 2003; 120: 641-6.
3. Allen MJ, Myer BJ, Khokher AM, Rushton N, Cox TM. Pro-inflammatory cytokines and the pathogenesis of Gaucher disease: increased release of interleukin-6 and interleukin-10. QJ Med. 1997; 90: 19-25.
4. Allen MJ, Hollak CEM, Evers L, Aerts JM, and van Oers MHJ: Elevated level of MCSF, sCD 14 and IL6 in type I Gaucher disease. Blood Cells Mol Dis. 1999; 23: 201-12.
5. Balicki D, Beutler E. Gaucher disease. Medicine (Baltimore). 1995; 74: 305-23.
6. Baumgartner RN, Stauber PM, Koehler KM, Romero L, Garry PJ. Associations of fat and muscle masses with bone mineral in elderly men and women. Am J Clin Nutr. 1996; 63: 365-72.
7. Bembi B, Ciana G, Mengel E, Terk MR, Martini C, Wenstrup RJ. Bone complications in children with Gaucher disease Br J Radiol. 2002; 75 (Suppl 1): A37-A44.
8. Boot RG, Renkema GH, Strijland A, van Zonneveld AJ, Aerst JM. Cloning of cDNA encoding chitotriosidase, a human chitinase produced by macrophages. J Biol Chem. 1995; 270: 26252-6.
9. Cenarro A, Pocovi M, Giraldo P, Garcia-Otin AL, Ordovas JM. Plasma lipoprotein responses to enzyme-replacement in Gaucher's disease. Lancet. 1999; 353: 642-3.
10. Ciana G, Martini C, Leopaldi A, Tamaro G, Katouzian F, Ronfani L, Bembi B. Bone markers alterations in patients with type 1 Gaucher disease. Calcif Tissue Int. 2003; 72: 185-9.
11. Ciana G, Addobbati R, Tamaro G, Leopaldi A, Nevyjel M, Ronfani L, Vidoni L, Pittis MG, Bembi B. Gaucher disease and bone: laboratory and skeletal mineral density variation during a long period of enzyme replacement therapy. J Inherit Metab Dis. 2005; 28: 723-32.
12. Cohen IJ, Katz K, Kornreich L, Horev G, Frish A, Zaizov R. Low-dose high frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crisis in patients with severe juvenile onset type I Gaucher disease. Blood Cells Mol Dis. 1998; 24: 296-302.
13. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Voght TM. Bone density at various sites for prediction of hip fractures The Study of Osteoporotic Fractures Research Group. Lancet. 1993; 341: 72-5.
14. Corssmit EPM, Hollak CEM, Endert E, van Oers MHJ, Sauerwein HP, Romijin JA. Increased basal glucose production in Type I Gaucher's disease. J Clin Endocrinol Metab. 1995; 80: 2653-7.
15. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporosis Int. 2005; 16: 670-6.
16. Drugan C, Jebeleanu G, Grigorescu-Sido P, Caillaud C, Cracium AM. Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease. Blood Cells Mol Dis. 2002; 28: 13-20.
17. Eastell R, Robins SP, Colwell T, Assiri AM, Riggs BL, Russell RG. Evaluation of bone turnover in Type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporos Int. 1993; 3: 255-60.
18. Fiore CE, Barone R, Pennisi P, Pavone V, Riccobens S. Bone ultrasonometry, bone density, and turnover markers in type I Gaucher disease. J Bone Miner Res. 2002; 20: 34-8.
19. Gery L, Zigler JS, Brady RO, Barranger JA. Selective effects of glucocerebroside (Gaucher's storage material) on macrophage cultures. J Clin Invest. 1981; 68: 1182-8.
20. Hollak CEM, Corssmit EPM, Aerts JMFG, Endert E, Sauerwein HP, Romijn JA, van Oers MHJ. Differential effects of enzyme replacement therapy on manifestations of Type I Gaucher disease. Am J Med. 1997; 103: 185-91.
21. Koprivica V, Stone DL, Park JK, Callahan M, Frisch A, Cohen IJ, Tayebi N, Sidransky E. Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet. 2000; 66: 1777-86.
22. Lebel E, Dweck A, Foldes AJ, Golowa Y, Itzchaki M, Zimran A, Elstein D. Bone density changes with enzyme therapy for Gaucher disease. J Bone Miner Metab. 2004; 22: 597-601.
23. Lim S, Joung H, Shin SC, Lee HK, Kim KS, Shin EK, Kim HY, Lim MK, Cho SI. Body composition changes with age have gender-specific impacts on bone mineral density. Bone. 2004; 35: 792-8.
24. Makovey J, Naganathan V, Sambrook P. Gender differences in relationships between body composition components, their distribution and bone mineral density: a cross-sectional opposite sex twin study. Osteoporosis Int. 2005; 16: 1495-505.
25. Matsuo T, Douchi T, Nakae M, Uto H, Oki H, Nagata Y. Relationship of upper body fat distribution to higher regional lean mass and bone mineral density. J Bone Miner Metab. 2003; 21: 179-83.
26. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999; 281: 249-54.
27. Michaelsson K, Bergstrom R, Mallmin H, Holmberg L, Wolk A, Ljunghall S. Screening for osteopenia and osteoporosis: selection by body composition. Osteoporosis Int. 1996; 6: 120-6.
28. Michelakakis H, Spanou C, Konyli A, Dimitriou E, Van Weely S, Hollak CE, Van Oers MH, Aerts JM. Plasma tumor Necrosis Facto alfa (TNF alfa) levels in Gaucher disease. Biochim Biophys Acta. 1996; 1317: 219-22.
29. Oliveri B, Zeni S, Lorenzetti MP, Aguilar G, Mautalen CA. Effect of one year residence in Antartica on Bone mineral Metabolism and body composition. Eur J Clin Nutr. 1999; 53: 88-91.
30. Ostlere L, Warner T, Meunier PJ, Hulme P, Hesp R, Watts RWE, Reeve J. Treatment of Type 1 Gaucher's Disease Affecting Bone with Aminohydroxypropylidene Bisphosphonate (Pamidronate). QJ Med. 1991; 79: 503-5115.
31. Pastores GM, Wallenstein S, Desnick RJ, Luckey MM. Bone density in type I Gaucher disease. J Bone Miner Res. 1996; 11: 1801-7.
32. Pluijm SMF, Visser M, Smit JH, Popp-Snijders C, Roos J C, Lips P. Determinants of bone mineral density in older men and women: Body composition as mediator. J Bone Miner Res. 2001; 16: 2142-51.
33. Proctor DN, Melton III LJ, Khosla S, Crowson CS, O'Connor MK, Riggs L. Relative influence of physical activity, muscle mass and strength on bone density. Osteoporos Int. 2000; 11: 944-52.
34. Reid IR, Lindsay D, Plank D, Evans MC. 1992 Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. J Clin Endocrinol Metab. 1992; 75: 779-82.
35. Rosenthal DI, Doppelt SH, Mankin HJ, Dambrosia JM, Xavier RJ, McKusik KA, Rosen BR, Baker J, Niklason NW, Suvimol CH, Miller SP, Brady RO, Barton NW. Enzyme replacement therapy for Gaucher's disease: skeletal responses to macrophages-targeted glucocerebrosidase. Pediatrics. 1995; 96: 629-37.
36. Rudzki Z, Okori K, Machaczka M, Rucinska M, Papla B, Skotnicki AB. Enzyme replacement therapy reduces Gaucher cell burden but may accelerate osteopenia in patients with type 1 disease - a histological study. Eur J Haematol. 2003; 70: 273-81.
37. Schiffman R, Mankin H, Dambrosia JM, Xavier RJ, Kreps C, Hill SC, Barton NW, Rosenthal DI. Decreased Bone Density in splenectomized enzyme replacement therapy. Blood Cells Molecules and diseases. 2002; 28: 288-96.
38. Stowens DW, Teitelbaum SL, Kahn AJ, Barranger JA. Skeletal complications of Gaucher disease. Medicine (Baltimore). 1985; 64: 310-22.
39. Sundeep K, Atkinson E, Riggs L. Relationship between body composition and bone mass in women. J Bone Miner Res. 1996; 11: 857-63.
40. Valimaki MJ, Tahtela R, Jones JD, Peterson JM, Riggs BL. Bone resorption in healthy osteoporotic women: comparison markers of serum carboxy-terminal telopeptide of type I collagen and urinary pyridinium cross-links. Eur J Endocrinol. 1994; 131: 258-62.
41. Vega E, Bagur A, Mautalen CA: Densidad Mineral ósea en mujeres osteoporöticas y normales de Buenos Aires. Medicina (Buenos Aires). 1993; 53: 211-6.
42. Walsh MC, Hunter GR, Livingstone MB. Sarcopenia in premenopausal and postmenopausal women with osteopenia, osteoporosis and normal bone mineral density. Osteoporos Int. 2006; 17: 61-7.
43. Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B. Skeletal aspects of Gaucher disease: a review. Brit Med J. 2002; 75 (suppl 1): A2-A12.
44. Wenstrup RJ, Bailey L, Grabowsky GA, Moskovitz J, Oestreich AE, Wu W, Sun S. Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood. 2004; 104: 1253-7.
45. Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, Hangartner TN. Effect of Enzyme Replacement Therapy with imiglucerase on BMD in Type I Gaucher Disease. J Bone Miner Res. 2007; 22:19-26.
46. Wittich A, Oliveri MB, Rotemberg E, Mautalen C: Body composition of professional football (soccer) players determined by dual X ray absorptiometry. J Clin Densitometry. 2001; 4: 51-5.
47. Zeni S, Wittich A, Di Gregorio S, Casco C, Oviedo A, Somoza J, Gómez Acotto C, Bagur A, González D, Portela ML, Mautalen C: Utilidad Clínica de los marcadores de formación y resorción ósea. Acta Bioquímica Clínica Latinoamericana. 2001; 35: 3-36.